With new PhI­II da­ta in hand, Der­ma­vant lines up top­i­cal pso­ri­a­sis con­tender for a sprint to the fin­ish line

In the next cou­ple months, Der­ma­vant CEO Todd Za­vod­nick says he’ll sprint to the FDA with tap­inarof, the com­pa­ny’s “cos­met­i­cal­ly el­e­gant” van­ish­ing cream to treat …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER